Author: Park, Hongzoo ; Heo, Ryeon ; Kang, Minji ; Choi, Il-Whan ; Jung, Won-Kyo ; Song, Geehyun ; Jung, Hee Seok ; Seo, Mi Seon ; Park, Won Sun ; An, Jin Ryeol

BACKGROUNDOlanzapine, an FDA-approved atypical antipsychotic, is widely used to treat schizophrenia and bipolar disorder. In this study, the inhibitory effect of olanzapine on voltage-dependent K⁺ (Kv) channels in rabbit coronary arterial smooth muscle cells was investigated.METHODSElectrophysiological recordings were performed in freshly isolated coronary arterial smooth muscle cells.RESULTSOlanzapine inhibited the Kv channels in a concentration-dependent manner with an IC₅₀ value of 7.76 ± 1.80 µM and a Hill coefficient of 0.82 ± 0.09. Although olanzapine did not change the steady-state activation curve, it shifted the inactivation curve to a more negative potential, suggesting that it inhibited Kv currents by affecting the voltage sensor of the Kv channel. Application of 1 or 2 Hz train pulses did not affect the olanzapine-induced inhibition of Kv channels, suggesting that its effect on Kv channels occurs in a use (state)-independent manner. Pretreatment with DPO-1 (Kv1.5 subtype inhibitor) reduced the olanzapine-induced inhibition of Kv currents. In addition, pretreatment with guangxitoxin (Kv2.1 subtype inhibitor) and linopirdine (Kv7 subtype inhibitor) partially decreased the degree of Kv current inhibition. Olanzapine induced membrane depolarization.CONCLUSIONFrom these results, we suggest that olanzapine inhibits the Kv channels in a concentration-dependent, but state-independent, manner by affecting the gating properties of Kv channels. The primary Kv channel target of olanzapine is the Kv1.5 subtype.

01 Nov 2020·EBioMedicineQ1 · MEDICINE

SP6616 as a Kv2.1 inhibitor efficiently ameliorates peripheral neuropathy in diabetic mice

Q1 · MEDICINE

ArticleOA

Author: Zhou, Jinpei ; Chen, Yun ; Zhu, Xialin ; Shen, Xu ; Hu, Lihong ; Xu, Xu ; Huang, Xi ; Xu, Xiaoju ; Lu, Yin ; Wang, Jiaying

BACKGROUNDDiabetic peripheral neuropathy (DPN) is a common complication of diabetes severely afflicting the patients, while there is yet no effective medication against this disease. As Kv2.1 channel functions potently in regulating neurological disorders, the present work was to investigate the regulation of Kv2.1 channel against DPN-like pathology of DPN model mice by using selective Kv2.1 inhibitor SP6616 (ethyl 5-(3-ethoxy-4-methoxyphenyl)-2-(4-hydroxy-3-methoxybenzylidene)-7-methyl-3-oxo-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate) as a probe.METHODSSTZ-induced type 1 diabetic mice with DPN (STZ mice) were defined at 12 weeks of age (4 weeks after STZ injection) through behavioral tests, and db/db (BKS Cg-m^+/+Lepr^db/J) type 2 diabetic mice with DPN (db/db mice) were at 18 weeks of age. SP6616 was administered daily via intraperitoneal injection for 4 weeks. The mechanisms underlying the amelioration of SP6616 on DPN-like pathology were investigated by RT-PCR, western blot and immunohistochemistry technical approaches against diabetic mice, and verified against the STZ mice with Kv2.1 knockdown in dorsal root ganglion (DRG) tissue by injection of adeno associated virus AAV9-Kv2.1-RNAi. Amelioration of SP6616 on the pathological behaviors of diabetic mice was assessed against tactile allodynia, thermal sensitivity and motor nerve conduction velocity (MNCV).FINDINGSSP6616 treatment effectively ameliorated the threshold of mechanical stimuli, thermal sensitivity and MNCV of diabetic mice. Mechanism research results indicated that SP6616 suppressed Kv2.1 expression, increased the number of intraepidermal nerve fibers (IENFs), improved peripheral nerve structure and vascular function in DRG tissue. In addition, SP6616 improved mitochondrial dysfunction through Kv2.1/CaMKKβ/AMPK/PGC-1α pathway, repressed inflammatory response by inhibiting Kv2.1/NF-κB signaling and alleviated apoptosis of DRG neuron through Kv2.1-mediated regulation of Bcl-2 family proteins and Caspase-3 in diabetic mice.INTERPRETATIONOur work has highly supported the beneficial of Kv2.1 inhibition in ameliorating DPN-like pathology and highlighted the potential of SP6616 in the treatment of DPN.FUNDINGPlease see funding sources.

01 Dec 2018·Clinical and Experimental Pharmacology and PhysiologyQ4 · MEDICINE

ETA as a novel Kv2.1 inhibitor ameliorates β‐cell dysfunction and hyperglycaemia

Q4 · MEDICINE

Article

Author: Quan, Lingling ; Du, Mengfan ; Chen, Jing ; Zhu, Zhiyuan ; Zhou, Tingting ; Zhao, Tong

AbstractThe Kv2.1 channel plays an important role in the regulation against pancreatic β‐cell dysfunctions. Therefore, it is regarded as a promising target for drug discovery against type 2 diabetes. In the present study, we found that the small molecule 4‐ethoxy‐N‐{[6‐(2‐thienyl)‐7H‐[1,2,4]triazolo[3,4‐b][1,3,4]thiadiazin‐3‐yl]methyl}aniline (ETA), a novel Kv2.1 inhibitor, may be capable of promoting glucose‐stimulated insulin secretion and protecting from apoptosis in pancreatic INS‐832/13 cells. The assay of ETA on type 2 diabetic mice induced by high‐fat diet (HFD)/streptozocin (STZ) confirmed its potency in ameliorating glucose homeostasis. ETA administration reduced fasting blood glucose and glycated haemoglobin levels, improved oral glucose tolerance, and increased serum insulin levels in HFD/STZ mice. Mechanism study demonstrated that ETA protected INS‐832/13 cells involving the regulation against protein kinase B and extracellular‐regulated protein kinase 1/2 signalling pathways. Our study has confirmed the underlying regulation of Kv2.1 against β‐cell function and also addressed the potential of ETA as a lead compound in the treatment of type 2 diabetes mellitus.

100 Deals associated with TAT-C1aB

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Stroke	Preclinical	US	University of Pittsburgh	-
Alzheimer Disease	Discovery	US	University of Pittsburgh	-
Brain Injuries	Discovery	US	University of Pittsburgh	-
Ischemic stroke	Discovery	US	University of Pittsburgh	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

TAT-C1aB

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation